Sarker, D., Reid, A. H. M., Yap, T. A., de Bono, J. S. (2009) Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer. CLINICAL CANCER RESEARCH, 15 (15). pp. 4799-4805. ISSN 1078-0432

Full text not available from this repository.

Abstract

Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase pathway is increasingly implicated in prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the rapidly evolving therapeutic implications of targeting it. In particular, we highlight the importance of the appropriate selection of agents and combinations, and the critical role of predictive and pharmocodynamic biomarkers.

Item Type:	Article
Authors (ICR Faculty only):	De-Bono, Johann
All Authors:	Sarker, D., Reid, A. H. M., Yap, T. A., de Bono, J. S.
Uncontrolled Keywords:	ANDROGEN RECEPTOR; BIOCHEMICAL RECURRENCE; TUMOR SUPPRESSION; PTEN EXPRESSION; FISH ANALYSIS; AKT; KINASE; GENE; PROGRESSION; PROTEIN
Research teams:	ICR divisions > Cancer Therapeutics > Cancer Biomarkers ICR divisions > Clinical Studies > Cancer Biomarkers ICR divisions > Clinical Studies > Prostate Cancer Targeted Therapy Group
Depositing User:	Users 10 not found.
Date Deposited:	25 Aug 2009 07:43
Last Modified:	11 Jul 2017 10:38
URI:	http://publications.icr.ac.uk/id/eprint/8568

Actions (login required)

View Item